Navigating Phenotypic Screening & Biology-First Strategies for Novel Induced Proximity Therapeutics

• Assessing the strengths, limitations and translational value of phenotypic screening for discovering novel proximity therapeutics
• Comparing biology-first and chemistry-first approaches, and how each guides hit identification, mechanistic validation and modality selection
• Exploring how biology-first strategies and complex disease-relevant assays can unlock non-degrader modalities such as stabilisers, modulators and activators
• Integrating AI-driven modelling and in silico cooperativity prediction with phenotypic and mechanistic workflows to accelerate molecular glue discovery

Speakers:

Radoslaw Nowak

Professor

The University of Bonn

Zoran Rankovic

Professor & Director, Chemical Biology, & Centre for Protein Degradation

Institute of Cancer Research

Juan Carlos Mobarec

Head Computational Structural Biology

AstraZeneca